

RED – HF Trial

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia

Study Phase III

Purpose

To determine the efficacy of treatment of anemia with darbepoetin alfa compared to placebo on the composite of time to death from any cause or first hospital admission for worsening HF in subjects with symptomatic left ventricular systolic dysfunction and anemia.

The study population will include those who meet the following inclusion/exclusion criteria, some of which are:

Inclusion criteria

- Demographics: >18 years of age
- HF of at least 3 months duration and of NYHA class II, III or IV
- Hemoglobin between 9.0 g/dL and 12.0 g/dL
- Left ventricular ejection fraction equal to or less than 40%

Exclusion criteria

- Subjects have had a recent cardiovascular event, unstable cardiovascular conditions, or any major surgery (cardiac or non-cardiac) within 3 months prior to randomization;
- Subjects with medical or laboratory abnormality that would make this the subject inappropriate for entry into this trial
- Subjects require treatment with aspirin > 325 mg/day
- Subjects with known hypersensitivity to celecoxib, ibuprofen, naproxen, aspirin or esomeprazole, etc.

To inquire if you are eligible for this study or hear more about it, please contact:

Pentucket Medical Associates
Clinical Research Office
(978) 469-5494